Table 1.
Sample no. | Grade | FIGO stage |
---|---|---|
1 | Poor | Ia |
2 | Poor | IIIa |
3 | Poor | Ib |
4 | Poor | Ib |
5 | Poor | IIIa |
6 | Poor | Ib |
7 | Poor | Ib |
8 | Poor | IIIa |
9 | Poor | IIIa |
10 | Poor | IIb* |
11 | Mod | Ib |
12 | Mod | Ic |
13 | Mod | IIb* |
14 | Mod | IIIa |
15 | Mod | Ic |
16 | Mod | Ic |
17 | Mod | Ic |
18 | Mod | Ia |
19 | Mod | Ib |
20 | Mod | IIb |
21 | Well | Ib |
22 | Well | Ib |
23 | Well | Ia |
24 | Well | Ic |
25 | Well | IIIa |
26 | Well | Ib |
27 | Well | Ib |
28 | Well | Ib |
29 | Well | Ia |
30 | Well | Ia |
All endometrial adenocarcinomas studied were of pure or predominantly of endometrioid type. There were no pure serous or clear cell subtypes in the series, and none of the tumors showed carcinosarcoma.∗ In these two samples myometrial invasion was <50%.